NCT01190163

Brief Summary

This is a comparative trial between oxytocin alone and dinoprostone for cervical ripening in unfavorable cervix pregnant women with 38 or more weeks of gestational age.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
170

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jun 2010

Geographic Reach
1 country

4 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2010

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 26, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 27, 2010

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2012

Completed
Last Updated

August 23, 2012

Status Verified

August 1, 2012

Enrollment Period

1.6 years

First QC Date

August 26, 2010

Last Update Submit

August 22, 2012

Conditions

Keywords

Vaginal Birth delivery within 24 hours and C-section rate

Outcome Measures

Primary Outcomes (1)

  • Vaginal birth delivery within 24 hours and C-section rate

    24 hours

Secondary Outcomes (3)

  • Treatment failure rate

    24 hours

  • Uterine hyperstimulation and/or fetal distress

    24 hours

  • Use of additional oxytocin

    24 hours

Study Arms (2)

A

EXPERIMENTAL
Drug: Dinoprostone

B

ACTIVE COMPARATOR
Drug: Oxytocin

Interventions

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Singleton pregnancy
  • Gestational age ≥ 38 weeks
  • Fetal cephalic presentation
  • Bishop score \< 6

You may not qualify if:

  • No uterine scar (no previous delivery by caesarean section)
  • No more than 3 previous vaginal births
  • No condition that disallows use of prostaglandins for induction of labor
  • Premature rupture of the membranes
  • Oligohydramnios

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

Ribeirão Preto, São Paulo, Brazil

Location

Hospital Municipal Universitário - Faculdade de Medicina do ABC

São Bernardo do Campo, São Paulo, Brazil

Location

Hospital M Boi Mirim

São Paulo, São Paulo, Brazil

Location

Hospital Maternidade Leonor Mendes de Barros

São Paulo, São Paulo, Brazil

Location

MeSH Terms

Interventions

DinoprostoneOxytocin

Intervention Hierarchy (Ancestors)

Prostaglandins EProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological FactorsPituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Clinical Development Support

    Ferring Pharmaceuticals

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2010

First Posted

August 27, 2010

Study Start

June 1, 2010

Primary Completion

January 1, 2012

Study Completion

January 1, 2012

Last Updated

August 23, 2012

Record last verified: 2012-08

Locations